ICU Medical (NASDAQ:ICUI) Issues FY24 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $5.40-5.70 for the period, compared to the consensus EPS estimate of $5.24. ICU Medical also updated its FY 2024 guidance to 5.400-5.700 EPS.

Wall Street Analysts Forecast Growth

ICUI has been the subject of several research reports. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Wednesday. Jefferies Financial Group began coverage on ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Finally, KeyCorp boosted their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Stock Performance

Shares of ICU Medical stock traded down $4.20 on Friday, hitting $167.76. The company had a trading volume of 37,793 shares, compared to its average volume of 274,538. The company has a current ratio of 2.29, a quick ratio of 1.08 and a debt-to-equity ratio of 0.75. The business has a 50-day simple moving average of $176.32 and a 200-day simple moving average of $142.19. ICU Medical has a 52 week low of $82.82 and a 52 week high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, topping the consensus estimate of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The firm had revenue of $580.07 million for the quarter, compared to the consensus estimate of $574.77 million. As a group, sell-side analysts anticipate that ICU Medical will post 3.81 EPS for the current year.

Insider Activity at ICU Medical

In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. The trade was a 16.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,502 shares of company stock valued at $6,573,496 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.